Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15443

Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients

Title: Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients
Authors : Piédrola, Ignacio
Martínez-López, Sara
Gradillas Nicolás, Ana
Villaseñor Solis, Alma Cristina
Alonso-Herranz, Vanesa
Sánchez Vera, Isabel
Escudero Lirola, Esther
Martín Antoniano, Isabel Adoración
Varona Arche, José Felipe
Navarro Ruiz, Andrés
Castellano Vázquez, José María
Muñoz Morón, Úrsula
Sádaba Argaiz, María Cruz
Keywords: Natural antibodiesCOVID-19IgMInflammationLipidomicLysophosphatidylcholineLysophosphatidylethanolaminePhosphatidylinositol
Publisher: Frontiers Media
Citation: Piedrola I, Martinez S, Gradillas A, et al. Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients. Front Immunol. 2023;14:1188786. https://doi.org/10.3389/fimmu.2023.1188786
Abstract: Background: Antibodies to lipids are part of the first line of defense against microorganisms and regulate the pro/anti-inflammatory balance. Viruses modulate cellular lipid metabolism to enhance their replication, and some of these metabolites are proinflammatory. We hypothesized that antibodies to lipids would play a main role of in the defense against SARS-CoV-2 and thus, they would also avoid the hyperinflammation, a main problem in severe condition patients. Methods: Serum samples from COVID-19 patients with mild and severe course, and control group were included. IgG and IgM to different glycerophospholipids and sphingolipids were analyzed using a high-sensitive ELISA developed in our laboratory. A lipidomic approach for studying lipid metabolism was performed using ultra-high performance liquid chromatography coupled to electrospray ionization and quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS). Results: Mild and severe COVID-19 patients had higher levels of IgM to glycerophosphocholines than control group. Mild COVID-19 patients showed higher levels of IgM to glycerophosphoinositol, glycerophosphoserine and sulfatides than control group and mild cases. 82.5% of mild COVID-19 patients showed IgM to glycerophosphoinositol or glycerophosphocholines plus sulfatides or glycerophosphoserines. Only 35% of severe cases and 27.5% of control group were positive for IgM to these lipids. Lipidomic analysis identify a total of 196 lipids, including 172 glycerophospholipids and 24 sphingomyelins. Increased levels of lipid subclasses belonging to lysoglycerophospholipids, ether and/or vinyl-ether-linked glycerophospholipids, and sphingomyelins were observed in severe COVID-19 patients, when compared with those of mild cases and control group. Conclusion: Antibodies to lipids are essential for defense against SARS-CoV-2. Patients with low levels of anti-lipid antibodies have an elevated inflammatory response mediated by lysoglycerophospholipids. These findings provide novel prognostic biomarkers and therapeutic targets.
URI: http://hdl.handle.net/10637/15443
Rights : http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
OpenAccess
ISSN: 1664-3224
Issue Date: 23-Jun-2023
Center : Universidad San Pablo-CEU
Appears in Collections:Medicina





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.